Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Actavia Life Sciences's operating cash flow per share for the
three
months ended in Mar. 2024 was $0.00.
Actavia Life Sciences's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Actavia Life Sciences's Operating Cash Flow per Share or its related term are showing as below:
RASP's 3-Year OCF Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16.85 * Ranked among companies with meaningful 3-Year OCF Growth Rate only.
Actavia Life Sciences Operating Cash Flow per Share Related Terms
Actavia Life Sciences Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Actavia Life Sciences's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Actavia Life Sciences Operating Cash Flow per Share Chart
RASP vs BWV, FNCH, CWBR: Operating Cash Flow per Share Comparison
For the Biotechnology subindustry, Actavia Life Sciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Actavia Life Sciences Price-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Actavia Life Sciences's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Actavia Life Sciences's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $0.00 mean?
Actavia Life Sciences (RASP) has a Operating Cash Flow per Share of $0.00 as of Mar. 2024. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Actavia Life Sciences and its competitors.
Is Actavia Life Sciences' Operating Cash Flow per Share too high?
Actavia Life Sciences' current Operating Cash Flow per Share is $0.00.
How does Actavia Life Sciences' Operating Cash Flow per Share compare to BWV and FNCH?
Actavia Life Sciences' Operating Cash Flow per Share of $0.00 can be compared against companies in the Biotechnology industry. The industry median Operating Cash Flow per Share is 16.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Biotechnology company?
The median Operating Cash Flow per Share among Biotechnology companies is 16.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Actavia Life Sciences and its competitors. For the Biotechnology industry, the median Operating Cash Flow per Share is 16.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Actavia Life Sciences's current Operating Cash Flow per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actavia Life Sciences stock overvalued right now?
Actavia Life Sciences (RASP) has a current Operating Cash Flow per Share of $0.00. The current Operating Cash Flow per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Actavia Life Sciences (RASP), the current Operating Cash Flow per Share is $0.00 as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RASP has been successfully added to your 
